The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Member discount codes
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Society Publications

Society Publications


The Antibody Society has participated in research resulting in numerous publications about antibody therapeutics, including:

  1. Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs 2023; 15(1). doi.org/10.1080/19420862.2022.2153410.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2022, as of November 2022.
  2. Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs 2022; 14(1). doi.org/10.1080/19420862.2021.2014296
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2021, as of November 2021.
  3. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs 2021; 13(1). doi.org/10.1080/19420862.2020.1860476
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2020, as of November 2020.
  4. Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19. Antibody Therapeutics. 2020.
    In March 2020, the Chinese Antibody Society, in collaboration with The Antibody Society, initiated the “COVID-19 Antibody Therapeutics Tracker” (https://chineseantibody.org/covid-19-track/) program to track the antibody-based COVID-19 interventions in preclinical and clinical development globally. This paper presents exploratory data analyses and visualization to demonstrate the latest trends of COVID-19 antibody development, based on data for over 150 research and development programs and molecules included in the Tracker as of August 8th, 2020.
  5. Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020; 12(1). 
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2019, as of November 2019.
  6. Reichert JM. Anticorps médicaments  – un regard américain sur un présent et un futur fascinants [Antibody therapeutics: an American view of an amazing present and future]. Med Sci (Paris). 2019;35(12):924–925.
    This paper provides an overview of the antibody therapeutics landscape as of 2019 and offers an outlook on the future.
  7. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery 2019; 18(8):585-608.
    This paper reviews the current bispecific antibody landscape from a mechanistic perspective, and includes a comprehensive overview of the clinical pipeline.
  8. Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs 2019; 11(2):219-238.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2018, as of November 2018.
  9. Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs 2018; 10(2):183-203.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2017, as of November 2017.
  10. Reichert JM. Antibodies to watch in 2017. MAbs 2017; 9(2):167-181.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2016, as of November 2016.

Select pipeline data derived from this research is available in the Members Only section of the Society’s website.

In addition, the Adaptive Immune Receptor Repertoire Community of The Antibody Society has endorsed and published papers including:

  1. Arnaout RA, Prak ETL, Schwab N, Rubelt F. Adaptive Immune Receptor Repertoire Community. The Future of Blood Testing Is the Immunome. (Frontiers in Immunology, 2021).
  2. Christley et al. The ADC API: a web API for the programmatic query of the AIRR Data Commons (Frontiers in Big Data, 2020).
    This paper outlines the API (Application Programming Interface) for curating and sharing data in the AIRR Data Commons (ADC).
  3. Lees et al. OGRDB: a reference database of inferred immune receptor genes introduces a new database for storing immunoglobulin and T-cell receptor genes inferred from AIRR-seq data (Nucleic Acids Research, 2020).
    This paper describes the Open Germline Receptor Database (https://ogrdb.airr-community.org), a public resource for the submission, review and publication of previously unknown receptor germline sequences together with supporting evidence.
  4. Ohlin et al. Inferred Allelic Variants of Immunoglobulin Receptor Genes: A System for Their Evaluation, Documentation, and Naming (Frontiers in Immunology, 2019)
    This paper summarizes recommendations developed by the IARC—focusing, to begin with, on human IGHV genes—with the goal of facilitating the acceptance of inferred allelic variants of germline IGHV genes.
  5. Vander Heiden et al. AIRR Community Standardized Representations for Annotated Immune Repertoires (Frontiers in Immunology, 2018)
    This paper describes the standardized data representations for storing and sharing annotated antibody and T cell receptor data.
  6. Rubelt et al. Adaptive Immune Receptor Repertoire Community recommendations for sharing immune-repertoire sequencing data (Nature Immunology, 2017, 18(12):1274-1278)
    This paper reports the Community’s recommendations for a minimal set of metadata that should be used to describe an AIRR-seq data set when published or when deposited in a AIRR-compliant repository.
  7. Breden et al. Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data (Frontiers in Immunology, 2017)
    This paper introduced the goals of the AIRR Community and urged researchers to join our efforts.

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • The Antibody Society announces the election of new Directors and Officers January 26, 2023
  • AIRR Data Commons and iReceptor Science Gateway Start Major Collaboration with Type-1 Diabetes Researchers January 11, 2023
  • FDA approves Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease January 6, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals